First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of SPR720, a Novel Oral Bacterial DNA Gyrase (GyrB) Inhibitor for Mycobacterial Infections

Angela K. Talley,a Archie Thurston,b Grayson Moore,a Vipul K. Gupta,a Myriah Satterfield,a Erika Manyak,a Suzanne Stokes,a,b Aaron Dane,b David Melnicka

aSpero Therapeutics, Inc., Cambridge, Massachusetts, USA
bADME Solutions, Inc., San Diego, California, USA
bDaneStat Consulting, Macclesfield, United Kingdom

ABSTRACT

SPR720 (phosphate prodrug of SPR719) is a novel aminobenzimidazole bacterial DNA gyrase (GyrB) inhibitor in development for nontuberculous mycobacterial pulmonary disease (NTM-PD) and pulmonary tuberculosis. SPR719 has demonstrated activity against clinically relevant mycobacteria in vitro and in murine and hollow-fiber infection models. This phase 1 randomized, double-blind, placebo-controlled, single ascending dose (SAD)/multiple ascending dose (MAD) trial evaluated the safety, tolerability, and pharmacokinetics of SPR720/SPR719. A total of 96 healthy volunteers (n = 8/cohort, 3:1 randomization) received SPR720 (or placebo) as single oral doses ranging from 100 to 2,000 mg or repeat total daily doses ranging from 500 to 1,500 mg for 7 or 14 days. SPR720 was well tolerated at daily doses of up to 1,000 mg for up to 14 days. Across SAD/MAD cohorts, the most common adverse events (AEs) were gastrointestinal (nausea, vomiting, and diarrhea) and headache, all of mild or moderate severity and dose dependent. No serious AEs were reported. The median SPR719 T\textsubscript{max} ranged from 2.8 to 8.0 h across cohorts, and the t\textsubscript{1/2} ranged from 2.9 to 4.5 h and was shown to be dose independent. Dosing with food decreased SPR719 plasma exposure by approximately 20%. In the MAD cohorts, SPR719 plasma exposure declined approximately 40% between days 1 and 7, suggesting induction of an elimination pathway. However, plasma AUC\textsubscript{0-24} was comparable between days 7 and 14. The results of this first-in-human study suggest that predicted therapeutic exposures of SPR719 can be attained with a once-daily oral administration of SPR720. (This study has been registered at ClinicalTrials.gov under registration no. NCT03796910.)

KEYWORDS

DNA gyrase inhibitor, aminobenzimidazole, nontuberculous mycobacteria, Mycobacterium avium complex, Mycobacterium tuberculosis, pharmacokinetics, SPR720, DNA gyrase inhibitor

Nontuberculous mycobacterial (NTM) pulmonary infection causes a chronic, progressive lung disease (NTM-PD) that occurs through inhalation of mycobacteria from environmental sources, especially in water and soil (1). Clinically relevant NTM species include Mycobacterium avium complex (MAC; consisting of M. avium, M. intracellulare, and M. chimaera), M. abscessus, M. xenopi, and M. kansasi (1). The pathophysiology of NTM-PD is poorly understood. In 2018, an estimated 75,000 to 105,000 people in the United States were diagnosed with NTM lung infection, with a higher frequency in older adults, and particularly in older nonsmoking women and men with COPD (2, 3). The prevalence of NTM-PD is increasing worldwide and is associated with increased health care costs and poor outcomes (1, 4–11).
No oral antimicrobial agents are currently approved for the treatment of NTM pulmonary infections, so current treatment guidelines are based on available clinical trial data for existing antibiotics (12). Recommended regimens vary by pathogen species and are guided by in vitro susceptibility testing. Current treatment guidelines for NTM-PD recommend prolonged treatment for at least 12 months after culture conversion with a three-drug approach comprised of azithromycin and two other drugs (rifampin and ethambutol, streptomycin, or intravenous amikacin) (12, 13). Even in the setting of prolonged combination therapy, outcomes are poor and often complicated by treatment-limiting adverse effects, resulting in high relapse and mortality rates (4, 14–17).

New effective treatment options for NTM are needed. SPR720 is a chemically stable phosphate prodrug that converts rapidly to SPR719, the active moiety, in vivo. It belongs to a novel class of antibacterial agents, the amino-benzimidazoles, which targets the ATPase subunits of bacterial DNA gyrase and, when present, topoisomerase, by a mechanism which is distinct from that of the fluoroquinolones. SPR720 is in clinical development for the treatment of NTM-PD and pulmonary tuberculosis (18). SPR719 has potent antimycobacterial activity comparable to clarithromycin and rifampin across clinically relevant mycobacterial species in vitro, including M. avium (19), M. kansasii, M. ulcerans, M. marinum, and M. chimaera (20, 21), with no evidence of cross-resistance to other standard-of-care agents (20–22). The efficacy of SPR719 against these mycobacterial species has been further established in murine models of infection and hollow-fiber studies with demonstrated additive activity of SPR719 in combination with clarithromycin and ethambutol (22–24). Preclinical studies to date support the further clinical evaluation of SPR720 as a candidate oral antimicrobial agent for the treatment of NTM-PD and pulmonary tuberculosis. We report here the results from a first-in-human study of SPR720 evaluating the safety, tolerability, and pharmacokinetics (PK) of SPR720/SPR719 using a single ascending dose (SAD)/multiple ascending dose (MAD) in healthy volunteers.

RESULTS

A total of 96 subjects were randomized, 56 in the SAD phase and 40 in the MAD phase. Baseline characteristics were comparable between treatment groups for both SAD and MAD phases (Table 1), except for a higher mean age in the elderly cohort of the SAD phase. The majority of subjects were male and Caucasian. All subjects completed the study and were included in the safety and PK analyses.

Safety/tolerability. Across SAD cohorts, 21 (37.5%) subjects reported 40 treatment-emergent adverse events (TEAEs). Of the 42 SAD subjects who received SPR720, 18 (42.9%) reported 35 TEAEs. A higher proportion of subjects reported TEAEs in the 1,500-mg and 2,000-mg dose groups (66.7 and 100.0%, respectively) compared to the lower-dose 100- to 1,000-mg cohorts (16.7 to 33.3%) (Table 2). All TEAEs were of mild or moderate severity. The most common TEAEs were gastrointestinal (nausea, vomiting, and diarrhea) and headache. No serious TEAEs were reported, and no deaths occurred.

Across MAD cohorts, 19 (47.5%) subjects reported 113 TEAEs. Of the 30 MAD subjects who received SPR720, 18 (60.0%) reported a total of 101 TEAEs (Table 2). A higher

| Parameter | SAD phase | MAD phase |
|-----------|-----------|-----------|
| Parameter | Placebo (n = 14) | SPR720 (n = 42) | Placebo (n = 10) | SPR720 (n = 30) |
| Mean age (yr) ± SD* | 40.1 ± 14.6 | 39.0 ± 16.0 | 32.9 ± 12.1 | 35.4 ± 9.5 |
| No. male (%) | 12 (85.7) | 36 (85.7) | 9 (90.0) | 27 (90.0) |
| Mean body wt (kg) ± SD | 81.8 ± 9.4 | 80.6 ± 10.5 | 79.0 ± 9.7 | 78.4 ± 9.6 |
| Mean BMI (kg/m²) ± SD | 26.5 ± 2.7 | 26.5 ± 2.8 | 25.8 ± 3.4 | 25.2 ± 3.0 |
| No. (%) Caucasian | 14 (100.0) | 42 (100.0) | 8 (80.0) | 30 (100.0) |

*The mean age ± the SD for the elderly cohort was 67.8 ± 2.6 years.

**BMI, body mass index.
**TABLE 2 Incidence of treatment-emergent adverse events in SAD and MAD groups**

| Preferred term | Placebo, overall (n = 14) | Cohort 1, 100 mg (n = 6) | Cohort 2, 250 mg (n = 6) | Cohort 3, 500 mg (n = 6) | Cohort 4, 1,000 mg, fasted (n = 6) | Cohort 4, 1,000 mg, fed (n = 6) | Cohort 5, 1,500 mg (n = 6) | Cohort 6, 2,000 mg (n = 6) | Elderly, 500 mg (n = 6) | Overall, SPR720 (n = 42) |
|----------------|---------------------------|--------------------------|--------------------------|--------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|--------------------------|--------------------------|
| SAD            |                           |                          |                          |                          |                               |                               |                               |                               |                          |                          |
| Any TEAE       | 3 (21.4)                  | 1 (16.7)                 | 2 (33.3)                 | 1 (16.7)                 | 1 (16.7)                     | 0                             | 4 (66.7)                     | 6 (100)                      | 3 (50.0)                 | 18 (42.9)                |
| Nausea         | 0                          | 0                        | 0                        | 0                        | 0                             | 0                             | 4 (66.7)                     | 5 (83.3)                     | 0                        | 9 (21.4)                 |
| Headache       | 1 (7.1)                   | 0                        | 0                        | 0                        | 1 (16.7)                     | 0                             | 3 (50.0)                     | 3 (50.0)                     | 0                        | 7 (16.7)                 |
| Vomiting       | 0                          | 0                        | 0                        | 0                        | 0                             | 0                             | 3 (50.0)                     | 5 (83.3)                     | 0                        | 8 (19.0)                 |
| Diarrhea       | 0                          | 0                        | 0                        | 0                        | 1 (16.7)                     | 0                             | 2 (33.3)                     | 0                            | 3 (7.1)                  |                          |
| Abdominal discomfort | 0                   | 0                        | 1 (16.7)                 | 0                        | 0                             | 0                             | 1 (16.7)                     | 1 (2.4)                      |                          |                          |
| Amylase increased | 0                    | 0                        | 0                        | 0                        | 0                             | 0                             | 0                            | 0                            | 0                        |                          |
| Dyspepsia      | 0                          | 0                        | 0                        | 0                        | 0                             | 0                             | 0                            | 0                            | 0                        |                          |
| Neuralgia      | 0                          | 0                        | 0                        | 0                        | 0                             | 0                             | 0                            | 0                            | 0                        |                          |
| Rhinorrhea     | 0                          | 0                        | 0                        | 0                        | 0                             | 0                             | 0                            | 0                            | 0                        |                          |
| Skin abrasion  | 0                          | 1 (16.7)                 | 0                        | 0                        | 0                             | 0                             | 0                            | 0                            | 0                        |                          |
| Toothache      | 0                          | 1 (16.7)                 | 0                        | 0                        | 0                             | 0                             | 0                            | 0                            | 0                        |                          |

**MAD**

| Preferred term | Placebo, overall, 7 days (n = 10) | Cohort 1, 100 mg, 7 days (n = 6) | Cohort 2, 1,000 mg, 7 days (n = 6) | Cohort 3, 1,500 mg, 7 days (n = 6) | Cohort 4, 500 mg, 14 days (n = 6) | Cohort 5, 1,000 mg, 14 days (n = 6) | Overall, MAD, SPR720 (n = 30) |
|----------------|----------------------------------|----------------------------------|------------------------------------|----------------------------------|-----------------------------------|------------------------------------|-------------------------------|
| Any TEAE       | 1 (100)                          | 4 (66.7)                         | 6 (100)                            | 4 (66.7)                         | 1 (16.7)                          | 3 (50.0)                          | 18 (60.0)                     |
| Diarrhea       | 1 (100)                          | 2 (33.3)                         | 4 (66.7)                           | 4 (66.7)                         | 0                                 | 3 (50.0)                          | 13 (43.3)                    |
| Headache       | 0                                | 2 (33.3)                         | 3 (50.0)                           | 2 (33.3)                         | 1 (16.7)                          | 0                                 | 8 (26.7)                     |
| Nausea         | 0                                | 2 (33.3)                         | 3 (50.0)                           | 3 (50.0)                         | 0                                 | 1 (16.7)                          | 7 (23.3)                     |
| Vomiting       | 0                                | 1 (16.7)                         | 2 (33.3)                           | 1 (16.7)                         | 0                                 | 0                                 | 4 (13.3)                     |
| Abdominal pain | 0                                | 2 (33.3)                         | 1 (16.7)                           | 0                                | 0                                 | 0                                 | 3 (10.0)                     |
| Back pain      | 0                                | 1 (16.7)                         | 0                                  | 0                                | 1 (16.7)                          | 0                                 | 2 (6.7)                      |
| Abdominal discomfort | 0                | 1 (16.7)                         | 0                                  | 0                                | 0                                 | 0                                 | 1 (3.3)                      |
| Abdominal pain upper | 0           | 1 (16.7)                         | 0                                  | 0                                | 1 (16.7)                          | 0                                 | 1 (3.3)                      |
| Contusion      | 0                                | 1 (16.7)                         | 0                                  | 0                                | 1 (16.7)                          | 0                                 | 1 (3.3)                      |
| Gastroesophageal reflux disease | 0          | 0                                | 0                                  | 0                                | 1 (16.7)                          | 0                                 | 1 (3.3)                      |
| Insomnia       | 0                                | 1 (16.7)                         | 0                                  | 0                                | 0                                 | 0                                 | 1 (3.3)                      |
| Lipase increased | 0                       | 0                                | 0                                  | 0                                | 1 (16.7)                          | 0                                 | 1 (3.3)                      |
| Oropharyngeal pain | 0                       | 1 (16.7)                         | 0                                  | 0                                | 0                                 | 0                                 | 1 (3.3)                      |
| Pancreatic enzymes increased | 0                        | 0                                | 1 (16.7)                          | 0                                | 0                                 | 0                                 | 1 (3.3)                      |
| Rash           | 0                                | 0                                | 1 (16.7)                           | 0                                | 0                                 | 0                                 | 1 (3.3)                      |
| Syncope        | 0                                | 1 (16.7)                         | 0                                  | 0                                | 0                                 | 0                                 | 1 (3.3)                      |
proportion of subjects reported TEAEs in the 7-day dose cohorts (66.7, 100, and 66.7% for the 500-, 1,000-, and 1,500-mg groups, respectively) than in the 14-day cohorts (16.7 and 50% for the 500- and 1,000-mg groups, respectively), which likely represents improved tolerability with continued dosing. All TEAEs were of mild to moderate severity and resolved without treatment. The most common TEAEs were gastrointestinal (diarrhea, nausea, and vomiting) and headache. No serious TEAEs were reported, and no deaths occurred.

One subject in the MAD 1,500-mg (750 mg q12h) dose group terminated dosing on day 6 due to a transient elevation in pancreatic enzymes reported as a moderate (grade 2 [CTCAE]) AE but remained in the study for follow-up visits. Peak values of amylase were 226 U/liter (2.3× upper limit of normal [ULN]) and lipase were 427 U/liter (7.1× ULN) on study day 5. Trough plasma SPR719 concentrations exceeded 1,000 ng/ml in this subject throughout the dosing period (range, 4,580 to 1,680 ng/ml from day 2 through day 5). The subject was asymptomatic, and clinical laboratory findings resolved without treatment. Transient elevations in alanine aminotransferase (ALT) levels (>1.5× ULN to <3× ULN) were observed in three subjects from the 14-day cohorts (500 and 1,000 mg); but no cases of Hy's Law occurred. There were no clinically significant changes in vital signs or 12-lead electrocardiogram (ECG) parameters during the study.

**Pharmacokinetics.** Due to rapid and extensive conversion of SPR720 to active moiety SPR719 in vivo, plasma concentrations of SPR720 across all cohorts were low and irregular following oral administration of SPR720. Therefore, characterization of SPR720 PK were best represented by assessment of SPR719 PK parameters.

(i) **Single ascending dose.** In the SAD phase, mean plasma SPR719 concentrations increased with increasing dose of SPR720 (Fig. 1). The PK parameters of SPR719 are shown in Table 3. The median $T_{\text{max}}$ for SPR719 ranged from 2.8 to 8.0 h across cohorts, and the mean elimination half-life ($t_{1/2}$) ranged from 2.9 h to 4.5 h. A dose–proportional increase in SPR719 $C_{\text{max}}$ and a greater-than-dose-proportional increase in SPR719 AUC were observed with increasing doses of SPR720 (Table 4). Administration of SPR720 following a high-fat meal resulted in a decrease of approximately 20% in geometric mean SPR719 plasma $C_{\text{max}}$, $\text{AUC}_{\text{last}}$, and $\text{AUC}_{\text{inf}}$ compared to the fasting state after a single 1,000-mg dose (Table 5). The effect of age on SPR719 PK following a single 500-mg dose of SPR720 was examined in healthy elderly subjects ≥65 years (SAD cohort 7) versus subjects <65 years in the SAD cohort 2. In the elderly versus younger subjects, geometric mean plasma SPR719 $C_{\text{max}}$ increased approximately 1.8-fold (1,760 ng/ml versus 2,860 ng/ml, respectively), and geometric mean $\text{AUC}_{0-24}$ increased approximately 1.5-fold (18,300 ng s² h/ml versus 21,000 ng s² h/ml, respectively). These data suggest a trend toward higher exposure of SPR719 in healthy elderly subjects. Urinary excretion of unchanged SPR719 was minimal (<0.5%) across SAD cohorts.

(ii) **Multiple ascending dose.** In the MAD phase, SPR719 plasma concentrations increased with increasing dose of SPR720 (Fig. 2). The PK profile of SPR719 was characterized by a median $T_{\text{max}}$ of 4 h and a mean $t_{1/2}$ that ranged from 1.7 to 5.1 h (Table 6). Dose-proportionality analysis showed that the SPR719 plasma $C_{\text{max}}$ and $\text{AUC}_{0-24}$ increased in a greater-than-dose-proportional manner with increasing doses of SPR720 (Table 7). Repeat administration of SPR720 was associated with a decrease in plasma exposure of SPR719 over 14 days. For the 500- and 1,000-mg 7-day dose groups, the geometric mean SPR719 plasma $C_{\text{max}}$ was similar at day 1 compared to day 7, with a <10% decrease from day 1 to day 7. However, for the 1,500-mg (750 mg q12h) 7-day group, geometric mean $C_{\text{max}}$ decreased approximately 44% from day 1 to day 7. The geometric mean plasma SPR719 plasma AUC decreased by 41 to 46% from day 1 to day 7 across these three cohorts. Similarly, in the 14-day 500- and 1,000-mg (nonfasting) dose groups (MAD cohorts 4 and 5), the geometric mean SPR719 plasma AUC decreased by 34 to 40% from day 1 to day 7 (Table 8 and Fig. 2). However, between day 7 and day 14, the geometric mean SPR719 plasma AUC decreased by 10% for the 500-mg group and by 33% for the 1,000-mg group, suggesting that any induction of SPR719 elimination pathways was stabilizing between days 7 and 14. Trough...
concentrations of SPR719 remained stable and low between days 7 and 14 for the 500- and 1,000-mg groups. In contrast, trough concentrations of SPR719 with more frequent dosing (750 mg q12h) were notably higher (7.7- and 21.7-fold on days 2 and 7, respectively) versus that observed with 1,000-mg once-daily dosing (Table 9). Similar to the SAD cohort, excretion of unchanged SPR719 in urine (0 to 24 h) was low (<1.5%) after multiple doses of SPR720 for up to 14 days.

**DISCUSSION**

A total of 96 subjects (including 8 healthy elderly subjects, age ≥65 years) were randomized and received study drug. SPR720 was well tolerated at daily doses up to 1,000 mg over the maximum duration of 14 days. Across SAD/MAD cohorts, the most common adverse events (AEs) were gastrointestinal (nausea, vomiting, and diarrhea) and headache, all of mild or moderate severity and dose dependent. No serious AEs were reported. While slight elevations in ALT occurred in 3 subjects with 14 days of dosing, these were reversible and not clinically significant. There was a single

![Graph A](image1.png)

**FIG 1** Geometric mean plasma SPR719 concentration-time curves following single ascending doses (SAD) of SPR720 (A) and SP720 of 1,000 mg during fed and fasting states (B).
discontinuation adverse event related to an asymptomatic elevation in amylase and lipase in a subject receiving 750 mg of SPR720 twice daily, although there was no associated clinical or ultrasound evidence of acute pancreatitis.

Across SAD cohorts, minimal to low levels of the prodrug (SPR720) were observed, indicating efficient conversion of SPR720 to the active moiety, SPR719. In vitro studies using intestinal and liver S9 fractions have indicated that SPR720 is rapidly hydrolyzed to the active moiety SPR719. Intestinal alkaline phosphatase is reported to cleave phosphate ester prodrugs and is probably responsible for the conversion of SPR720 to SPR719. There were dose-proportional and greater-than-dose-proportional increases in exposure to the active moiety SPR719. Presystemic conversion of the phosphate prodrug SPR720 to the active moiety SPR719 is supported by data from the present study, in which plasma concentrations of SPR720 across all SAD and MAD cohorts were low across subjects and cohorts. Based on preclinical studies and studies in hepatic microsomes, the proposed metabolic pathway of SPR719 in humans is dealkylation, hydroxylation, or glucuronidation.

| Parameter | 100 mg (n = 6) | 250 mg (n = 6) | 500 mg (n = 6) | 1,000 mg, fasted (n = 6) | 1,500 mg (n = 6) | 2,000 mg (n = 6) | Slope (95% CI) |
|-----------|----------------|----------------|----------------|--------------------------|-----------------|----------------|----------------|
| Cmax (ng/ml) | 278 (58.3) | 2,75 (1–4) | 3.15 (65.4) | 1,360 (95.6) | 1,620 (174.6) | 1,650 (184.0) | 3.82 (132.0) |
| T1/2 (h) | 6,060 (44.7) | 6,900 (41.3) | 6,940 (40.8) | 6,980 (22.3) | 6,800 (22.3) | 6,780 (22.3) | 2.68 (93.7) |
| AUC0–24 (h s² ng/ml) | 5,100 (28.3) | 4,100 (28.3) | 4,300 (28.3) | 4,500 (28.3) | 4,500 (28.3) | 4,500 (28.3) | 1.04 (88.7) |
| AUC0–t (h s² ng/ml) | 5,100 (28.3) | 4,100 (28.3) | 4,300 (28.3) | 4,500 (28.3) | 4,500 (28.3) | 4,500 (28.3) | 1.04 (88.7) |
| AUC0–inf (h s² ng/ml) | 5,100 (28.3) | 4,100 (28.3) | 4,300 (28.3) | 4,500 (28.3) | 4,500 (28.3) | 4,500 (28.3) | 1.04 (88.7) |

aAUC0–24, area under the concentration-time curve from time zero to 24 h; AUCinf, area under the concentration-time curve extrapolated to infinity; AUCmax, area under the concentration-time curve from time zero to infinity; Cmax, maximum concentration; T1/2, elimination half-life; T1/2, time of maximum observed concentration. Cmax and AUC values are expressed as geometric means (% coefficient of variation [CV%]). T1/2 values are expressed as medians (ranges), and half-life (t1/2) values are expressed as arithmetic means. The lower limit of quantitation is 10 ng/ml; BQL assigned a value of missing.

bStatistical analysis of SPR719 dose proportionality in the SAD phase (fasted) revealed a significant increase in SPR719 exposure between 100 mg and 250 mg, but not between 250 mg and 500 mg. AUCmax, AUC0–24, and AUC0–t were significantly increased between 100 mg and 250 mg.

cSlope values for the comparison of SPR719 exposure between 100 mg and 250 mg were 1.58, 1.64, and 1.64, respectively, indicating a significant increase in SPR719 exposure between these doses.

dSlope values for the comparison of SPR719 exposure between 250 mg and 500 mg were 1.64, 1.64, and 1.64, respectively, indicating a significant increase in SPR719 exposure between these doses.

eSlope values for the comparison of SPR719 exposure between 500 mg and 1,000 mg were 1.64, 1.64, and 1.64, respectively, indicating a significant increase in SPR719 exposure between these doses.

fSlope values for the comparison of SPR719 exposure between 1,000 mg and 2,000 mg were 1.64, 1.64, and 1.64, respectively, indicating a significant increase in SPR719 exposure between these doses.

gSlope values for the comparison of SPR719 exposure between 100 mg and 1,000 mg were 1.64, 1.64, and 1.64, respectively, indicating a significant increase in SPR719 exposure between these doses.

hSlope values for the comparison of SPR719 exposure between 250 mg and 500 mg were 1.64, 1.64, and 1.64, respectively, indicating a significant increase in SPR719 exposure between these doses.

iSlope values for the comparison of SPR719 exposure between 500 mg and 1,000 mg were 1.64, 1.64, and 1.64, respectively, indicating a significant increase in SPR719 exposure between these doses.

jSlope values for the comparison of SPR719 exposure between 1,000 mg and 2,000 mg were 1.64, 1.64, and 1.64, respectively, indicating a significant increase in SPR719 exposure between these doses.

kSlope values for the comparison of SPR719 exposure between 100 mg and 250 mg were 1.64, 1.64, and 1.64, respectively, indicating a significant increase in SPR719 exposure between these doses.

lSlope values for the comparison of SPR719 exposure between 250 mg and 500 mg were 1.64, 1.64, and 1.64, respectively, indicating a significant increase in SPR719 exposure between these doses.

mSlope values for the comparison of SPR719 exposure between 500 mg and 1,000 mg were 1.64, 1.64, and 1.64, respectively, indicating a significant increase in SPR719 exposure between these doses.

nSlope values for the comparison of SPR719 exposure between 1,000 mg and 2,000 mg were 1.64, 1.64, and 1.64, respectively, indicating a significant increase in SPR719 exposure between these doses.

oSlope values for the comparison of SPR719 exposure between 100 mg and 1,000 mg were 1.64, 1.64, and 1.64, respectively, indicating a significant increase in SPR719 exposure between these doses.

pSlope values for the comparison of SPR719 exposure between 250 mg and 500 mg were 1.64, 1.64, and 1.64, respectively, indicating a significant increase in SPR719 exposure between these doses.

qSlope values for the comparison of SPR719 exposure between 500 mg and 1,000 mg were 1.64, 1.64, and 1.64, respectively, indicating a significant increase in SPR719 exposure between these doses.

rSlope values for the comparison of SPR719 exposure between 1,000 mg and 2,000 mg were 1.64, 1.64, and 1.64, respectively, indicating a significant increase in SPR719 exposure between these doses.

sSlope values for the comparison of SPR719 exposure between 100 mg and 250 mg were 1.64, 1.64, and 1.64, respectively, indicating a significant increase in SPR719 exposure between these doses.

tSlope values for the comparison of SPR719 exposure between 250 mg and 500 mg were 1.64, 1.64, and 1.64, respectively, indicating a significant increase in SPR719 exposure between these doses.

uSlope values for the comparison of SPR719 exposure between 500 mg and 1,000 mg were 1.64, 1.64, and 1.64, respectively, indicating a significant increase in SPR719 exposure between these doses.

vSlope values for the comparison of SPR719 exposure between 1,000 mg and 2,000 mg were 1.64, 1.64, and 1.64, respectively, indicating a significant increase in SPR719 exposure between these doses.
that SPR719 is predominantly metabolized by CYP3A4. Since the standard of care for NTM-PD is combination antibiotic therapy, the potential for drug-drug interactions with other anti-NTM agents such as the macrolides and rifamycins will need to be assessed.

One of the MAD cohorts also evaluated a 750-mg q12h dosing regimen for SPR720. Increasing the dosing frequency from once daily to q12h resulted in a substantial increase in the trough concentrations of SPR719 and SPR719, supporting once-daily dosing of SPR720. However, further PK and PD evaluations are warranted.

Nonclinical studies demonstrated that SPR719 is efficacious in an M. avium hollow-fiber infection model (HFIM) using a PK profile that supports once-daily dosing in humans (23). SPR720 also demonstrated efficacy in a chronic murine model of M. avium pulmonary infection, both alone and in combination with standard-of-care agents, resulting in statistically significant reduction in bacterial burden following the oral administration of SPR720 once daily (24). These data support the further development of SPR720 for the treatment of NTM-PD in humans.

Recommendations for the treatment of infections caused by NTM are based mostly on anecdotal data or expert opinion, with limited good-quality data available from randomized, controlled studies (5, 13, 25). Standard-of-care oral treatment includes azithromycin, rifampin, ethambutol, isoniazid, fluoroquinolones, doxycycline, linezolid, and trimethoprim-sulfamethoxazole (5, 12, 13). The administration of combinations of these drugs is required for treatment durations of up to 12 months following sputum culture conversion, and recurrence or re-infection occurs in approximately 50% of cases (4, 25, 26). In a recent retrospective study of 297 patients with NTM, 40% of patients who had susceptibility results available were resistant to amikacin, ethambutol, or rifampin (4). The standard-of-care medications often are poorly tolerated and potentially toxic, especially when used in combination (13, 25). Thus, new systemic treatment options are needed, in particular for patients with refractory or drug-resistant NTM lung disease (25).

A potential limitation of this study was the limited exposure in healthy subjects to SPR720, in particular with respect to safety and tolerability. This study also did not evaluate SPR720 in combination with other drugs used to treat NTM. However, this was a first-in-human study with SPR720 that used a study design to satisfy regulatory requirements for determining doses and regimens to advance for future studies. In addition, the study evaluated the PK and tolerability in fasted versus fed states, as well as in an elderly cohort.

SPR720 is a chemically stable phosphate prodrug which converts rapidly to SPR719, the active moiety, in vivo. It belongs to a novel aminobenzimidazole class of antibacterial agents which target the ATPase subunits of gyrase and, when present, topoisomerase, resulting in growth inhibition of a range of pathogens (18). SPR719 is structurally and mechanistically distinct from, and demonstrates no cross-resistance with, fluoroquinolones. SPR719 is active in vitro against clinically relevant NTM pathogens, including isolates which are resistant to currently used agents (27). SPR720 represents a

### Table 5: Statistical analysis of food effect on the PK of SPR719 following single oral 1,000 mg doses of SPR720

| Parameter | 1,000 mg, fasted (n = 6) | 1,000 mg, fed (n = 6) | Geometric LS mean ratio (%) 90% CI | Within-subject CV (%) |
|-----------|--------------------------|-----------------------|-----------------------------------|----------------------|
| C<sub>max</sub> (ng/ml) | 4,730 | 4,000 | 84.6 (69.9–102.4) | 16.6 |
| AUC<sub>last</sub> (h² ng/ml) | 56,500 | 45,100 | 79.9 (68.5–93.0) | 13.2 |
| AUC<sub>inf</sub> (h² ng/ml) | 56,800 | 45,200 | 79.6 (68.3–92.8) | 13.2 |

*Results were obtained using a fixed-effects ANOVA with fixed effects of treatment and subject. AUC<sub>inf</sub> area under the concentration-time curve (AUC) extrapolated to infinity; AUC<sub>last</sub> AUC from time of dosing to time of the last measurable concentration; CI, confidence interval; C<sub>max</sub> maximum plasma concentration; CV, coefficient of variation; LS mean, least-squares mean.*
promising approach to the treatment of NTM-PD because of its novel mechanism of action and once-daily oral dosing. The tolerability profile of SPR720 in this first-in-human study was mostly confined to gastrointestinal complaints and headache. Results from this study provide evidence that SPR720 is generally well tolerated with once-daily dosing and the SPR719 PK characteristics are suitable for once-daily administration. This study supports further clinical evaluation of SPR720 in patients with NTM-PD.

MATERIALS AND METHODS
This was a single-center, phase 1, randomized, double-blind, placebo-controlled, first-in-human study to assess the safety, tolerability, and PK of SPR720 (prodrug) and SPR719 (active moiety) following single or multiple ascending oral dose administrations of SPR720. This study was conducted according to the principles of the Declaration of Helsinki and Guidance on Good Clinical Practice. The study protocol, amendments, and informed consent forms were reviewed and approved by an Institutional Review Board. All subjects provided written informed consent prior to participating in any study activities. This study was registered at Clinicaltrials.gov under accession number NCT03796910.

FIG 2 Geometric mean plasma SPR719 concentration-time curves following multiple ascending doses (MAD) of SPR720 on days 1, 7, and 14.
SPR720, a GyrB Inhibitor for Mycobacterial Infections

Antimicrobial Agents and Chemotherapy

Study design. This was a two-part multicohort study enrolling 96 healthy volunteers (including a healthy elderly cohort of subjects aged ≥65 years). Each cohort enrolled 8 subjects, randomized 3:1 to receive SPR720 (6 subjects) or placebo (2 subjects). Each subject was assigned to only one cohort.

Dose escalation between cohorts took place following blinded review by the study Safety Monitoring Group of all available safety, tolerability, and PK data from the preceding dose level. SPR720 was supplied as 100- and 250-mg capsules for oral administration. Part 1 followed a single ascending dose (SAD) design in which six dose levels of SPR720 were evaluated (100, 250, 500, 1,000, 1,500, and 2,000 mg) in seven sequential cohorts, including a second 500-mg single dose group of healthy elderly subjects aged ≥65 years (Fig. 3). Each cohort followed a schedule where two subjects (one randomized to placebo and one randomized to SPR720) were dosed in a blinded manner at least 24 h prior to the remainder of the cohort. In the absence of any safety concerns in these first two subjects, dosing of the remainder of the cohort proceeded on schedule. Subjects in SAD cohorts 1 to 5 received a single oral SPR720 or placebo after an overnight fast of at least 10 h. Fasting continued until 4 h postdose. Subjects in cohort 4 (food effect cohort; 1,000 mg) received an additional dose administered under fed conditions in which subjects were provided a standard U.S. Food and Drug Administration high-fat and high-calorie breakfast (28), with study drug administration occurring approximately 30 min after the start of the meal. Following review of interim data from cohort 4 fasted/fed periods, which suggested no clinically meaningful effect of food on PK and tolerability, dosing in subsequent SAD (cohorts 6 and 7) and MAD (cohorts 3 to 5) cohorts allowed for administration of SPR720 or placebo without regard to meals (nonfasting state), typically following a standardized meal or snack, for improved tolerability.

During part 2 (MAD), subjects received repeat dose administration of SPR720 (or placebo) for 7 days (cohorts 1 to 3) or 14 days (cohorts 4 and 5). All doses were administered once daily, with the exception of SPR720 in the 7-day dose groups was administered in the fasting state; dosing in the 14-day dose groups was administered without regard to meals.

### Table 6: Summary of SPR719 PK parameters following oral administration of SPR720 in healthy volunteers: MAD phase

| SPR720 treatment (n) | Mean (% CV)* | Day | Cmax (ng/ml) | Tmax (h) | Cmax (ng/ml) | Tmax (h) | AUC0–12 (h s² ng/ml) | AUC0–24 (h s² ng/ml) | AUCinf (h s² ng/ml) | Accumulation ratio |
|---------------------|-------------|-----|--------------|----------|--------------|----------|---------------------|---------------------|------------------|------------------|
| 500 mg QD, 7-day dose group (6) | 1 | 2,470 (40.8) | 4.0 (4–8) | NC | 1,740 (78.6) | 4 (1–8) | 14,700 (41.5) | 16,800 (47.2) | NA | 0.593 (52.8) |
| | 7 | 2,420 (39.9) | 4.0 (4–8) | NC | 1,740 (78.6) | 4 (1–8) | 14,700 (41.5) | 16,800 (47.2) | NA | 0.593 (52.8) |
| 1,000 mg QD, 7-day dose group (6) | 1 | 5,610 (20.1) | 4.0 (4–8) | NC | 3,490 (56.0) | 4 (4–8) | 43,200 (24.5) | 57,000 (34.9) | NA | 0.593 (52.8) |
| | 7 | 5,110 (21.4) | 4.0 (4–8) | NC | 3,490 (56.0) | 4 (4–8) | 43,200 (24.5) | 57,000 (34.9) | NA | 0.593 (52.8) |
| 1,500 mg total daily dose (750 mg q12h), 7-day dose group (6) | 1 | 4,690 (24.0) | 4.0 (4–8) | NC | 3,130 (26.0) | 4 (4–8) | 31,300 (26.0) | 54,700 (39.7) | NA | 0.593 (52.8) |
| | 7 | 2,520 (34.8) | 4.0 (4–8) | NC | 3,130 (26.0) | 4 (4–8) | 31,300 (26.0) | 54,700 (39.7) | NA | 0.593 (52.8) |
| 500 mg QD, 14-day dose group (6) | 1 | 1,410 (48.5) | 4.0 (4–8) | NC | 8,140 (68.4) | 4 (4–8) | 8,140 (68.4) | 9,420 (75.7) | NA | 0.593 (52.8) |
| | 7 | 1,140 (72.8) | 4.0 (4–8) | NC | 5,680 (97.0) | 4 (4–8) | 5,680 (97.0) | 6,260 (100.6) | NA | 0.593 (52.8) |
| 1,000 mg QD, 14-day dose group (6) | 1 | 3,500 (28.6) | 4.0 (4–8) | NC | 27,500 (30.6) | 4 (4–8) | 27,500 (30.6) | 35,700 (25.8) | NA | 0.593 (52.8) |
| | 7 | 3,490 (56.0) | 4.0 (4–8) | NC | 19,400 (63.6) | 4 (4–8) | 19,400 (63.6) | 21,600 (68.7) | NA | 0.593 (52.8) |

*Table 7: Statistical analysis of SPR719 dose proportionality in the MAD phase

| Treatment day and group | Geometric LS mean | Parameter | Slope (95% CI) |
|------------------------|------------------|-----------|---------------|
| Day 1, fasted          | Cmax (ng/ml)     | 2,470     | 1.18 (0.60–1.76) |
| Day 2, fasted          | Cmax (ng/ml)     | 2,420     | 1.08 (0.50–1.65) |
| Day 1, fed             | Cmax (ng/ml)     | 1,410     | 1.42 (0.60–2.25) |
| Day 2, fed             | Cmax (ng/ml)     | 1,140     | 1.64 (0.72–2.55) |
| Day 1, 14d             | Cmax (ng/ml)     | 967       | 1.37 (0.26–2.49) |

*Results for Cmax and AUC were obtained using a regression analysis on log-transformed values versus log-transformed dose using the power model (including an additional term for fed/fasted status for the model incorporating all cohorts for part 2). AUC0–12, area under the concentration-time curve (AUC) from time zero to 12 h; AUC0–24, area under the concentration–time curve from time zero to 24 h; AUCinf, area under the concentration–time curve from time zero to infinity; Cmax, maximum concentration; Cmax, maximum plasma concentration; LS mean, least-squares mean; NA, not applicable. Dosing of SPR720 in the 7-day dose groups was administered in the fasting state; dosing in the 14-day dose groups was administered without regard to meals.

November 2021 Volume 65 Issue 11 e01208-21 aac.asm.org
methods and included the maximum plasma concentration (C_max) each study visit. Formed in fasted cohorts (with baseline and postdose ECG extractions). Adverse events were recorded at rate, physical examination, and assessment of ECG parameters. Continuous Holter monitoring was performed or over-the-counter medications with 7 days of randomization. Antigen (HBsAg) or hepatitis C antibody; a positive urine drug/alcohol test or history of substance or clinical laboratory testing (hematology, serum chemistry, and urinalysis), vital signs (blood pressure, heart rate, body temperature, and respiratory rate), ECG, and physical examination. Clinically signiﬁcant cardiac abnormalities, including clinically signiﬁcant cardiac abnormalities; a history of Clostridium difﬁcile infection; positive human immunodeﬁciency virus (HIV) antibody, hepatitis B surface antigen (HBsAg) or hepatitis C antibody; a positive urine drug/alcohol test or history of substance or alcohol abuse, documented hypersensitivity, or anaphylaxis to any medication or use of tobacco or nicotine-containing products within 30 days; consumption of grapefruit-containing products with 7 days; alcohol abuse, documented hypersensitivity, or anaphylaxis to any medication or use of tobacco or nicotine-containing products within 30 days; consumption of grapefruit-containing products with 7 days; receipt of any investigational drug or participation in a clinical trial within 30 days; or use of any prescription or over-the-counter medications with 7 days of randomization.

Study assessments. All AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA). TEAEs were deﬁned as existing conditions that worsened or events that occurred during the study after administration of study drug. Safety variables included clinical laboratory testing (hematology, serum chemistry, and urinalysis), vital signs (blood pressure, heart rate, body temperature, and respiratory rate), physical examination, and assessment of ECG parameters. Continuous Holter monitoring was performed in fasted cohorts (with baseline and postdose ECG extractions). Adverse events were recorded at each study visit.

Pharmacokinetic analysis. Pharmacokinetic parameters were evaluated using noncompartmental methods and included the maximum plasma concentration (C_max), area under the concentration (AUC)–time curve from time zero to last measurable time point (AUC_0–t), or from time zero to inﬁnity (AUC_0–inf), time to maximum concentration (T_max), and terminal half-life (t_1/2). In addition, the AUC-time curve from time zero to 12 or 24 h after the start of first dose (AUC_0–12 and AUC_0–24) was determined for MAD cohorts using noncompartmental methods. Data for AUC_0–last and AUC_0–inf were log transformed and analyzed using the trapezoidal rule.

In part 1 (SAD), blood samples for the determination of SPR720 and SPR719 plasma levels were obtained predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 8, 12, 24, 36, and 48 h postdose. Urine samples for of the 1,500-mg dose (MAD Cohort 3) that was administered as 750 mg q12h for improved tolerability based on review of data from SAD cohorts 5 (1,500 mg) and 6 (2,000 mg). Subjects in MAD cohorts 1 and 2 received SPR720 or placebo in the fasted state. Dosing in MAD cohorts 3 to 5 allowed for administration of SPR720 or placebo in a nonfasting state.

Subject selection. Adult male and female subjects aged 18 to 55 years (age ≥65 years for SAD cohort 7) who were assessed as medically healthy with no clinically signiﬁcant abnormalities based on physical examination, vital signs (temperature, heart rate, blood pressure, and respiratory rate), ECG, and clinical laboratory testing (serum chemistry, hematology, and urinalysis) were eligible. Females were of childbearing potential, and males used an acceptable form of contraception. Subjects were excluded from participation if they had a positive urine drug/alcohol test or history of substance or alcohol abuse, documented hypersensitivity, or anaphylaxis to any medication or use of tobacco or nicotine-containing products within 30 days; consumption of grapefruit-containing products with 7 days; receipt of any investigational drug or participation in a clinical trial within 30 days; or use of any prescription or over-the-counter medications with 7 days of randomization.

Study assessments. All AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA). TEAEs were deﬁned as existing conditions that worsened or events that occurred during the study after administration of study drug. Safety variables included clinical laboratory testing (hematology, serum chemistry, and urinalysis), vital signs (blood pressure, heart rate, body temperature, and respiratory rate), physical examination, and assessment of ECG parameters. Continuous Holter monitoring was performed in fasted cohorts (with baseline and postdose ECG extractions). Adverse events were recorded at each study visit.

Pharmacokinetic analysis. Pharmacokinetic parameters were evaluated using noncompartmental methods and included the maximum plasma concentration (C_max), area under the concentration (AUC)–time curve from time zero to last measurable time point (AUC_0–t), or from time zero to inﬁnity (AUC_0–inf), time to maximum concentration (T_max), and terminal half-life (t_1/2). In addition, the AUC-time curve from time zero to 12 or 24 h after the start of first dose (AUC_0–12 and AUC_0–24) was determined for MAD cohorts using noncompartmental methods. Data for AUC_0–last and AUC_0–inf were log transformed and analyzed using the trapezoidal rule.

In part 1 (SAD), blood samples for the determination of SPR720 and SPR719 plasma levels were obtained predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 8, 12, 24, 36, and 48 h postdose. Urine samples for

**TABLE 8** Summary of statistical analysis of SPR719 accumulation in MAD phase

| SPR720 group | Parameter | Geometric LS mean | Geometric LS mean accumulation ratio |
|--------------|-----------|-------------------|--------------------------------------|
|              |           | Day 1       | Day 7       | Day 14      | Day 7/day 1 | Day 14/day 1 |
| 500 mg (n = 6) | C_max (ng/ml) | 2,470      | 2,420      | 97.7 (73.9–129.3) | NA |
|              | AUC_0–24 (h s²/ng/ml) | 16,800   | 9,970      | 59.3 (39.4–89.2) | NA |
| 1,000 mg (n = 6) | C_max (ng/ml) | 5,610      | 5,100      | 90.9 (74.4–111.1) | NA |
|              | AUC_0–24 (h s²/ng/ml) | 57,000    | 30,600     | 53.7 (37.8–76.1) | NA |
| 1,500 mg (750 mg q12h) (n = 6) | C_max (ng/ml) | 4,490      | 2,520      | 56.1 (47.3–66.5) | NA |
|              | AUC_0–12 (h s²/ng/ml) | 29,200    | 17,300     | 59.2 (46.2–75.9) | NA |
| 500 mg (n = 6) | C_max (ng/ml) | 1,410      | 1,140      | 967         | 80.9 (48.5–135.2) | 68.7 (38.3–123.3) |
|              | AUC_0–24 (h s²/ng/ml) | 9,420     | 6,260      | 5,640       | 66.4 (31.8–138.7) | 59.9 (29.6–121.0) |
| 1,000 mg (n = 6) | C_max (ng/ml) | 3,500      | 3,490      | 2,500       | 99.9 (61.4–162.7) | 71.6 (45.1–113.6) |
|              | AUC_0–24 (h s²/ng/ml) | 35,700    | 21,600     | 14,500      | 60.4 (34.8–105.0) | 40.5 (27.2–60.4) |

*Mixed-effects ANOVA was performed on log-transformed data with the fixed effect of study day and a random effect of subjects. Parameter estimates for AUC_0–inf were calculated as a partial area based on the actual predose sampling time of the following day, where a bleed time deviation occurred at the 24-h time point and the k_el was not calculable. ANOVA, analysis of variance; AUC_0–inf, area under the concentration-time curve (AUC) from time zero to 12 h postdose; AUC_0–24, AUC from time zero to 24 h postdose; CI, confidence interval; C_max, maximum plasma concentration; LS mean, least-squares means; NA, not applicable. Dosing of SPR720 in the 7-day dose groups was administered in the fasting state; dosing in the 14-day dose groups was administered without regard to meals.

**TABLE 9** Trough concentrations of SPR719 by dose in the MAD phase

| Dose group | Geometric LS mean trough concn (ng/ml) at day* |
|------------|---------------------------------------------|
|            | 2      | 3      | 4      | 5      | 6      | 7      | 8      | 9      | 10     | 11     | 12     | 13     | 14     |
| 500 mg × 7 days | 20.8   | 9.7    | 7.1    | 5.7    | 5.0    | 5.0    | NA     | NA     | NA     | NA     | NA     | NA     | NA     |
| 1,000 mg × 7 days | 306    | 100    | 34.7   | 18.1   | 21.1   | 18.7   | NA     | NA     | NA     | NA     | NA     | NA     | NA     |
| 750 mg q12h × 7 days | 2,370   | 1,510  | 1,430  | 1,300  | 662    | 406    | NA     | NA     | NA     | NA     | NA     | NA     | NA     |
| 500 mg × 14 days | 12.4   | 8.5    | 7.2    | 7.0    | 6.6    | 7.2    | 8.6    | 5.7    | 8.1    | 11.5   | 8.3    | 5.0    | 7.4    |
| 1,000 mg × 14 days | 176    | 85     | 42.7   | 50.2   | 54.4   | 25.5   | 25.3   | 22.1   | 18.7   | 20.4   | 14.2   | 10.0   | 12.0   |

*NA, not applicable.
determination of SPR719 urinary excretion were collected predose, and pooled urine collections took place over the following intervals: 0 to 4 h, 4 to 8 h, 8 to 12 h, and 12 to 24 h postdose.

In part 2 (MAD), blood samples for the determination of SPR720 and SPR719 plasma concentrations were obtained predose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 8, and 12 h postdose (days 1, 7, and 14, where applicable) and additionally at 24, 36, and 48 h after the last/final dose (day 7 or 14). Trough (24 h) samples were collected within 15 min prior to each dose on days 2 to 6 (7-day cohorts) and days 2 to 14 (14-day cohorts). Urine samples for determination of SPR719 urinary concentrations were collected predose on day 1 and pooled urine collections took place over the following intervals: 0 to 4 h, 4 to 8 h, 8 to 12 h, and 12 to 24 h postdose on day 1 (SAD and MAD cohorts) and 24 to 48 h after the final dose on day 7 and day 14 (MAD cohorts). Validated liquid chromatography-tandem mass spectrometry bioanalytical assays were used to determine SPR720 and SPR719 plasma concentrations and SPR719 urine concentrations. The lower limit of quantitation was 10 ng/ml for all the analytes in both matrices.

**Statistical analysis.** The safety population included all subjects who received study drug. The PK population included all subjects with evaluable concentration-time profiles for each active dose level who had no major protocol violations that impacted PK. Plasma concentrations and PK parameters for SPR719 were summarized for each treatment with Phoenix WinNonlin version 6.4. For PK calculations, concentration values below the limit of quantitation were assigned a value of zero, and the actual time of sample collection was used.

**(i) Dose proportionality/independence.** For the SAD part of this study, dose proportionality was assessed by a regression analysis of the log-transformed $C_{\text{max,SPR719}}, AUC_{0-t,SPR719}$, and $AUC_{\text{inf,SPR719}}$ values versus the log-transformed dose using the power model with a fixed effect for log(dose). Dose independence was assessed for half-life by performing a regression analysis of the untransformed parameters versus dose with a fixed effect for dose. For each PK parameter, a point estimate and corresponding 95% confidence interval (CI) was calculated for the slope of the regression line. For the MAD part of the study, the dose proportionality assessment was performed separately for the fasted cohorts (cohorts 1 and 2) and fed cohorts (cohorts 3 to 5) using the same analysis method as described above. For day 1 and day 7, dose proportionality was assessed by performing a regression analysis of log-transformed $C_{\text{max,SPR719}}$...
and AUC_{\text{Cmax,12}} (day 7 only). The analysis was repeated for the additional MAD cohorts 4 and 5 at day 14 for C_{\text{Cmax}} and AUC_{\text{Cmax,12}}.

(ii) Food effect. After logarithmic transformation, C_{\text{Cmax}}, AUC_{\text{0-t}}, and AUC_{\text{Cmax}} values were analyzed with an analysis of variance (ANOVA), including fixed effects for treatment (fed or fasted) and subject. Point estimates and 90% CI values were constructed for the contrasts between treatments using the residual mean square error obtained from the ANOVA. The point and interval estimates were back-transformed to give estimates of the ratios of the geometric least-square mean (LS mean) and the corresponding 90% CI. Estimated geometric means are presented for each treatment.

(iii) Steady state. For each dose level, log-transformed trough concentration levels prior to the first dose each day (day 2 through to day 7/14) were analyzed with a mixed-effect ANOVA with the study day as a fixed effect and the subject as a random effect in order to establish whether and when steady-state had been attained for each dose level. Back-transformed ratios for the comparisons of each consecutive day (i.e., day 3/2 day) are presented along with the corresponding 90% CI.

(iv) Accumulation. For each MAD phase dose group, log-transformed C_{\text{Cmax}}, AUC_{\text{0-t}}, and AUC_{\text{Cmax}} values on day 1 and day 7 (or day 14, where applicable) were analyzed with an ANOVA with the study day as a fixed effect and the subject as a random effect. For comparison, point estimates and 90% CI values for the difference between day 7/14 and day 1 were constructed using the residual mean-square-error obtained from the ANOVA for each dose level. The point and interval estimates were back-transformed to give estimates of the ratios of the geometric least-square means and corresponding 90% CI values.

ACKNOWLEDGMENTS

We acknowledge the editorial assistance of Richard S. Perry in the development of the manuscript, which was supported by Spero Therapeutics, Cambridge, MA. Troy Lister (Spero Therapeutics, Inc.) assisted with development of the manuscript.

All authors were involved in data analysis and interpretation of study results. All authors were involved in preparation of the manuscript and reviewed and approved submission of the manuscript.

A.D. is an employee of DaneStat Consulting, Macclesfield, United Kingdom. A.T. is President of ADME Solutions, Inc., San Diego, CA. All other authors were employees of Spero Therapeutics, Cambridge, MA, at the time of this study.

This study was supported by Spero Therapeutics, Inc., Cambridge, MA.

REFERENCES

1. Bethencourt Mirabal A, Ferrer G. 2020. Lung nontuberculous mycobacterial infections. StatPearls Publishing, Treasure Island, FL. Accession date 16 November 2019.

2. Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR. 2012. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med 185:881–886. https://doi.org/10.1164/rcrm .201111-2016OC.

3. Strollo SE, Adjemian J, Adjemian MK, Prevots DR. 2015. The burden of pulmonary nontuberculous mycobacterial disease in the United States. Ann Am Thorac Soc 12:1458–1465. https://doi.org/10.1513/AnnalsATS.201503 -173OC.

4. Marras T, Stapleton JT, Roupheal N, Cneck B, Stout JE, El Sahly HM, Jackson L, Leyva FJ, Tomashek KM, Tibbals M, Watson N, Miller A, Charbek E, Siegner J, Sokol-Anderson M, Nayak R, Dahlberg G, Winokur P, Alaaedine G, Beydoun N, Sokolow K, Kown NP, Phillips S, Baker AW, Turner N, Walter E, Guy E, Frey S. 2021. Variability in the management of adults with pulmonary nontuberculous mycobacterial disease. Clin Infect Dis 72:1127–1137. https://doi.org/10.1093/cid/ciaa252.

5. Baldwin SL, Larsen SE, Ordway D, Cassell G, Coler RN. 2019. The complexities and challenges of preventing and treating nontuberculous mycobacterial diseases. PLoS Negl Trop Dis 13:e0007083. https://doi.org/10.1371/journal. pnpt.0007083.

6. Horne D, Skerratt S. 2019. Recent advances in nontuberculous mycobacterial lung infections. F1000Res 8:F1000 Faculty Rev-1710. https://doi.org/10.12688/f1000research.20096.1.

7. Marras TK, Mirsaiedi M, Chou E, Olivier KN, Santin M, Stout JE, Tortoli E, van Ingen J, Wagner D, Winthrop KL. 2020. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESC/IDSA clinical practice guideline. Clin Infect Dis 71:905–913. https://doi.org/10.1093/cid/ciaa1125.

8. Mirsaiedi M, Allen MB, Ebrahimi G, Schraufnagel D. 2015. Hospital costs in the US for pulmonary mycobacterial disease. Int J Mycobacteriol 4: 217–221. https://doi.org/10.1016/j.jmyco.2015.05.003.

9. Prevots DR, Marras TK. 2015. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin Chest Med 36: 13–34. https://doi.org/10.1016/j.ccm.2014.10.002.

10. Winthrop KL, Marras TK, Adjemian J, Zhang H, Wang P, Zhang Q. 2020. Incidence and prevalence of nontuberculous mycobacterial lung disease in a large U.S. managed care health plan, 2008–2015. Ann Am Thorac Soc 17:178–185. https://doi.org/10.1513/AnnalsATS.201804-236OC.

11. Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ, Andrejak C, Böttger EC, Brozek J, Griffith DE, Guglielmetti L, Huitt GA, Knight SL, Leitman P, Marras TK, Olivier KN, Santin M, Stout JE, Tortoli E, van Ingen J, Wagner D, Winthrop KL. 2020. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESC/IDSA clinical practice guideline. Clin Infect Dis 71:905–913. https://doi.org/10.1093/cid/ciaa1125.

12. Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, Leitch A, Loebinger MR, Milburn HJ, Nightingale M, Ormerod P, Shingadia D, Smith D, Whitehead N, Wilson R, Floto RA. 2017. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax 72:ii1–ii64. https://doi.org/10.1136/ thoraxjnl-2017-210927.

13. Jarand J, Davis JP, Cowie RL, Field SK, Fisher DA. 2016. Long-term follow-up of Mycobacterium avium complex lung disease in patients treated with regimens including clofazimine and/or rifampin. Chest 149:1285–1293. https://doi.org/10.1016/j.chest.2015.05.043.

14. Deshpande D, Gumbo T. 2011. Pharmacokinetic/pharmacodynamic-based treatment of disseminated Mycobacterium avium. Future Microbiol 6:433–439. https://doi.org/10.2217/fmb.11.25.

15. Marras TK, Vinnard C, Zhang Q, Hamilton K, Adjemian J, Eagle G, Zhang R, Chou E, Olivier KN. 2018a. Relative risk of all-cause mortality in patients with nontuberculous mycobacterial lung disease in a US managed care population. Respir Med 145:80–88. https://doi.org/10.1016/j.rmed.2018.10.022.
17. Mirsaedi M, Machado RF, Garcia JGN, Schraufnagel DE. 2014. Nontuberculous mycobacterial disease mortality in the United States, 1999–2010: a population-based comparative study. PLoS One 9:e91879. https://doi.org/10.1371/journal.pone.0091879.

18. Stokes SS, Vemula R, Pucci MJ. 2020. Advancement of GyrB inhibitors for treatment of infections caused by Mycobacterium tuberculosis and nontuberculous mycobacteria. ACS Infect Dis 6:1323–1331. https://doi.org/10.1021/acsinfecdis.0c00025.

19. Bermudez LE, Palmer A, Rubio A. 2018. Treatment of Mycobacterium avium subspecies hominissuis (MAH) infection with a novel gyrase inhibitor (SPR719/SPR720) was associated with a significant decrease in bacterial load as assessed in macrophages, biofilm, and in mice, poster SUN-540. ASM Microbe/American Society for Microbiology, Washington, DC.

20. Brown-Elliott BA, Rubio A, Wallace RJ, Jr. 2018. In vitro susceptibility testing of a novel benzimidazole, SPR719, against nontuberculous mycobacteria. Antimicrob Agents Chemother 62:e01503-18. https://doi.org/10.1128/AAC.01503-18.

21. Pidot S, Stinear T, Lister T, Rubio A. 2019. In vitro activity of SPR719 against non-tuberculosis mycobacterium strains of Mycobacterium ulcerans, Mycobacterium marinum, and Mycobacterium chimaera, poster AAR-750. ASM Microbe/American Society for Microbiology, Washington, DC.

22. Rubio A, Stapleton M, Verma D. 2018. Ordway: potent activity of a novel gyrase inhibitor (SPR719/SPR720) in vitro and in a prolonged acute Mycobacterium abscessus mouse model of infection, poster SUN-539. ASM Microbe/American Society for Microbiology, Washington, DC.

23. Deshpande D, Kuret D, Cirrincione K, Cotroneo N, Melnick D, Lister T, Stokes S, Gumbo T. 2020. Pharmacokinetics/pharmacodynamics of the novel gyrase inhibitor SPR719/SPR720 and clinical dose selection to treat pulmonary Mycobacterium avium-complex disease, poster 1659. IDWeek/IDSA, Arlington, VA.

24. Verma D, Peterson C, Stokes S, Cotroneo N, Ordway D. 2020. SPR720, a novel benzimidazole gyrase inhibitor, demonstrates potent efficacy against Mycobacterium avium ATCC 700898 in a chronic C3HeBFeJ mouse infection model, poster 1637. IDWeek/IDSA, Arlington, VA.

25. Cowman S, van Ingen J, Griffith DE, Loebinger MR. 2019. Non-tuberculous mycobacterial pulmonary disease. Eur Respir J 54:1900250. https://doi.org/10.1183/13993003.00250-2019.

26. Kwak N, Dalcolmo MP, Daley CL, et al. 2019. Mycobacterium abscessus pulmonary disease: individual patient data meta-analysis. Eur Respir J 54:1801991. https://doi.org/10.1183/13993003.01991-2018.

27. Murray B, Hall D, Cotroneo N, Critchley I, Pucci M, Stokes S, Pillar C. 2020. Evaluating the activity of SPR719, a novel aminobenzimidazole, against nontuberculous mycobacteria, poster 1274. IDWeek/IDSA, Arlington, VA.

28. Food and Drug Administration. 2019. Assessing the effects of food on drugs in INDs and NDAs: clinical pharmacology considerations. U.S. Food and Drug Administration, Bethesda, MD.